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Specific reaction over 0-1% occurred in 19 sera taken from 10 children, all of whom were under treatment with HGH. Only 4 of these children showed a slowing down of growth associated with the development of antibodies, 2 children permanently and 2 only for a period of three months with spontaneous recovery of growth rate and drop of antibodies. The level of antibodies which appears to cause growth inhibition is between 0-5 % and 1% binding capacity of the M.R.C. standard.
In all, 4 out of 42 children with isolated growth hormone deficiency have developed 'permanent' growth-retarding antibodies on HGH treatment. No children with other diagnoses have done so. Specific antibodies were not present in any of our patients before treatment.
All currently available growth hormone preparations are highly antigenic, and soon after treatment of children with human growth hormone (HGH) was begun patients were described whose initially increased rate of growth decreased abruptly as antibodies appeared in their blood (Prader et al., 1964) . The a further two whose growth was only stopped temporarily. Subjects The main patients in this study were 98 children who had been treated with HGH for periods between 6 months and 7 years. Of these, 38 had hyposomatotrophic short stature (or isolated growth hormone deficiency), 15 had craniopharyngiomas associated with failure to grow, 2 had pinealomas, and 1 tuberculous meningitis with short stature, 3 had panhypopituitarism of unknown cause, 16 were of short stature associated with low birthweight, 7 had genetic short stature, 6 had Tumer's syndrome, 2 had steroid-induced short stature, 2 had glycogen storage disease, and there were 6 with unknown diagnoses, probably chondrodystrophies.
In addition, 51 children, including normals, asthmatics, and some with congenital anomalies, none of whom was treated with HGH, were studied each on one or two occasions.
HGH prepared by a modification of Raben's method by Hartree (1966) Greenwood, Hunter, and Glover (1963) , with some modifications (Chalkley, 1969) . The specific activity varied between 130 and 250 ,uCi/,ug and the reagent blanks (i.e. the damaged hormone)
were 5-10%. When the reagent blanks rose to 20% the hormone was discarded.
All sera were tested against at least two preparations of labelled hormone in order to minimize any nonspecific effects due to the iodination damage.
Determination of antibodies. A radioimmunoassay using vertical electrophoresis in polyacrylamide gel was used (Chalkley, 1969) , modified from that of Fitschen (1964) , which was based on the original method described by Ormstein and Davis (1962) .
In this method, labelled HGH reacts with antibody in an upper gel layer of large pore size for 60 min. Separation takes place in the lower gel layer of small pore size. After 60 min the antigen-antibody complex has migrated 0-5 to 1-0 cm from the origin and the unbound HGH 2-0 to 2-5 cm. The labelled HGH therefore moves through the antibody layer, so that there is a close proximity of reagents during the reaction period.
The standard antiserum, 66/250, was used at three dilutions: 1: 6250, 1: 125,000 and 1: 250,000. The 1:6250 was prepared in bulk and frozen in 2-0 ml portions at -20 'C. One vial of this, when diluted for use, was sufficient for four assays.
Test sera were diluted 1:5 and 1:10 for preliminary assay. If the result was negative, the serum was reassayed at these dilutions against a different preparation of iodinated HGH. If the result was positive, the serum was reassayed at higher dilutions, until a dilution was reached which gave a percentage binding equivalent to that of the reagent blank.
All standards and sera were done in duplicate in each assay, except for the blanks, of which there were four per assay. The electrophoresis apparatus held 34 tubes, so that these consisted of 4 blanks, 3 standards in duplicate, and 6 sera in duplicate at two dilutions.
The lower gel layer was polymerized in each tube, and then the upper gel layer was added and photopolymerized in two stages. 80 ,u diluent (for blanks) or diluted antiserum or test serum were incorporated into the first stage, and 5 1ul iodinated HGH (= 31 pg HGH) were incorporated in the second stage. Electrophoresis took two hours at 2-5 mA/tube at 37 'C. After this, the upper gel layer was discarded and the lower gel layer divided into 'bound', i.e. the antigenantibody complex region, and 'free', containing the unbound HGH. These two portions were counted.
Calculation. The percentage HGH 'bound' by each serum sample was estimated by a technique which has for many years been established in bioassay (see Finney, 1952) . A plot of the percentage bound against antiserum dilution gives the familiar sigmoid curve, with about 90% bound at very low dilutions of antiserum and about 20% bound at very high dilutions. On probit paper, then, the percentage bound plotted against log dilution gives a straight line.
The standard antiserum is assayed at three dilutions and a straight line fitted by least squares to the three resulting points. Similarly the test serum sample is assayed at three (in this work more usually two) dilutions and a straight line fitted. Two comparisons may then be made between the two lines. First they can be examined for parallelism (Youden, 1951) and second the difference in log dilution between them corresponding to any given percentage bound can be estimated.
The percentage bound selected is 35% (Farr, 1958) because this is the midpoint of the probit curve, hence has the lowest error estimate. The final calculation is thus: Antibody Binding Capacity (ABC) as a percentage of standard antiserum capacity = 100 (log dilution at 350% bound of test serum-log dilution at 35% bound of standard antiserum). The actual calculations are simply carried out on an Olivetti desk computer.
The test for parallelism is of much importance, for non-parallelism between the assays indicates heterogeneity between the standard and the test serum and probably means non-specific antibodies are present. In Tables II to V assays which show non-parallelism significant at 5% are given one asterisk, and those at 10% a dagger. Note that we assume as null hypothesis that the assays are parallel, so that we must be failing to asterisk a number of assays which are really non-parallel (and hence non-specific, see below), rather than the other way around.
Growth. The 
Results
Specific and non-specific reactions. 280% of the serum samples from the children with short stature, and 31°% of the samples from the 'control' children gave positive ABC reactions. However all samples taken from the short children before HGH treatment, and all samples from the control children, showed significant non-parallelism to the standard and must be presumed to represent nonspecific antibodies. Many of the samples taken during HGH treatment also showed non-parallelism. Only 27 sera gave reactions which were possibly parallel and hence represent specific antibodies, and of these only 19 were also above 0-1 0, ABC. These 19 occurred in 10 individual children, all of whom had been treated with HGH.
It seems that there is a specific antibody to HGH down to about the level of 0 1°ABC, but not below. Out of 23 ABC values above 0 10%, only 4 were significantly non-parallel at the 500 level and a further 5 at the 10% level. Of the 25 specimens with ABC from 0 0250% to 0 09 %/, 19 were significantly non-parallel at 5 0/ and a further 2 at 10%. Of the 52 specimens with ABC from 0-005% to 0 0250, 50 were significantly nonparallel at 5% and a further 1 at 10%. Two sera which gave high ABC levels were used to see whether the addition of unlabelled HGH to the assay system would inhibit binding of labelled HGH (Frasier and Smith, 1966) . The sera were R.K. (Table II) 1* 340o ABC, and P.T. (Table IV) (Table I) . There seemed little difference, either in 'specific' or 'non-specific' reactions. At once it rose to 3 % and then 7 % before gradually declining.
The second patient, D.R. (Table III) , developed antibodies during the first six months on growth hormone, but they were insufficient in amount to stop his good response (10 0 cm/yr) during this time. During the second six months they rose much higher and his growth entirely ceased. The antibodies went down to insignificant levels after two years off the hormone and growth was resumed at the pre-HGH, hyposomatrotrophic rate. The third patient, P.T. (Table IV) , is interesting Our first patient, R.K., is curious in developing antibodies only after 18 months of treatment. Previous investigators (Frasier and Smith, 1966; Prader et al., 1964; Roth et al., 1964) have reported that growth-inhibiting antibodies appear always within the first three months of treatment.
Since none of our patients gave evidence of the presence of specific antibodies before treatment, it appears that the short stature is not due to autoimmunity to HGH in any of our cases. 
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